

CC-930 (Tanzisertib)

Catalog No: tcsc1544



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

899805-25-5

Formula:

$C_{21}H_{23}F_3N_6O_2$

Pathway:

MAPK/ERK Pathway

Target:

JNK

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 33 mg/mL (73.59 mM)

Alternative Names:

CC-930

Observed Molecular Weight:

448.44


Product Description

Tanzisertib (CC-930) is a potent **JNK1/2/3** inhibitor with **IC₅₀s** of 61/7/6 nM, respectively.

IC₅₀ & Target: IC₅₀: 61 nM (JNK1), 7 nM (JNK2), 6 nM (JNK3)^[1]

In Vitro: Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemagglutinin (IC₅₀=1 μM)^[1]. Tanzisertib (CC-930) (1-2 μM) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes^[2]. Tanzisertib (CC-930) blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis^[3].

In Vivo: Tanzisertib (CC-930) (10 and 30 mg/kg, p.o.) inhibits the production of TNFα by 23% and 77% in the acute rat LPS-induced TNFα production PK-PD model^[1]. Tanzisertib (CC-930) (150 mg/kg) prevents the development of fibrosis in different models, but can also induce the regression of pre-existing fibrosis^[3].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!